Table 3.
Potential anti-AD drugs identified by the L1000FWD analysis.
| n | DRUGS | similarity score | p-value | Z-score | combined score | Target(s) | Indication(s) |
|---|---|---|---|---|---|---|---|
| 1 | flunisolide | −0.102 | 1.33E-03 | 1.87 | −5.37 | cytochrome P450 inhibitor | allergic rhinitis |
| 2 | xylazine | −0.102 | 1.43E-03 | 1.87 | −5.31 | Xylazine HCl is α2 class of adrenergic receptor agonist. | anesthetic |
| 3 | salmeterol | −0.102 | 1.91E-03 | 1.82 | −4.95 | adrenergic receptor agonist | asthma, chronic obstructive pulmonary disease (COPD), bronchospasm |
| 4 | thalidomide | −0.102 | 1.91E-03 | 1.79 | −4.88 | tumor necrosis factor production inhibitor | immunomodulatory agent |
| 5 | lenalidomide | −0.102 | 1.99E-03 | 1.8 | −4.86 | anticancer agent | multiple myeloma, mantle cell lymphoma (MCL), myelodysplastic diseases (MDS) |
| 6 | desoximetasone | −0.102 | 1.93E-03 | 1.74 | −4.74 | glucocorticoid receptor agonist | corticosteroid-responsive dermatoses |